TRVI
Trevi Therapeutics, Inc.Company Information
- Company Name
- Trevi Therapeutics, Inc.
- CIK
- CIK0001563880
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TRVI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TRVI
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 39,473
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 149,649,088
- Shares outstanding
- 156,602,158
- Ownership
- 95.56%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -9.24%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 54 | 19 | 19 | 57 | 117 | 19 | 34 | 16 | 13 | 14 | 32 | 26 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 326 | 176 | 192 | 198 | 207 | 106 | 109 | 67 | 72 | 77 | 88 | 94 | ||||||
| Marketable Securities Current | 265 | 152 | 169 | 138 | 87 | 84 | 74 | 49 | 57 | 59 | 51 | 63 | ||||||
| Prepaid Expense Current | 4 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 3 | 4 | 4 | ||||||
| Other Assets Current | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 4 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Right Of Use Asset | - | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 331 | 180 | 193 | 199 | 208 | 107 | 111 | 69 | 74 | 79 | 89 | 96 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 3 | 2 | 4 | 3 | 3 | 1 | 3 | 2 | 2 | 2 | 2 | 1 | ||||||
| Accrued Liabilities Current | 5 | 5 | 6 | 6 | 6 | 5 | 7 | 7 | 5 | 3 | 4 | 4 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 9 | 7 | 10 | 9 | 9 | 7 | 11 | 9 | 7 | 5 | 6 | 5 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Finance Lease Liability Current | - | - | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities | 9 | 7 | 10 | 10 | 10 | 8 | 11 | 10 | 8 | 6 | 7 | 6 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 683 | 515 | 513 | 511 | 508 | 397 | 387 | 334 | 329 | 322 | 322 | 321 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 322 | 172 | 183 | 190 | 198 | 99 | 100 | 59 | 66 | 72 | 83 | 90 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -361 | -343 | -330 | -321 | -310 | -297 | -287 | -276 | -262 | -250 | -239 | -231 | ||||||
| Liabilities And Stockholders Equity | 331 | 180 | 193 | 199 | 208 | 107 | 111 | 69 | 74 | 79 | 89 | 96 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 142 | 128 | 128 | 128 | 122 | 100 | 94 | 75 | 73 | 69 | 68 | 64 | ||||||
| Shares Outstanding | 142 | 128 | 128 | 128 | 122 | 100 | 94 | 75 | 73 | 69 | 68 | 64 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTrevi Therapeutics, Inc. (TRVI) — SEC Financial Statements & Analysis
Trevi Therapeutics, Inc. (TRVI) is a pharmaceutical preparations company, incorporated in DE. Trevi Therapeutics, Inc. trades on Nasdaq as: TRVI. Trevi Therapeutics, Inc. (TRVI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Trevi Therapeutics, Inc. carries a market cap of $2.92B, a P/E ratio of -57.15x, a P/B ratio of 9.08x, an enterprise value of $2.87B, and an EV/EBITDA multiple of -48.24x. On profitability, it posts a Return on Equity (ROE) of -19.66%, a Return on Assets (ROA) of -18.97%, and a Return on Invested Capital (ROIC) of -34.12%. Per share, it reports EPS of $-0.33, diluted EPS of $-0.33, free cash flow per share of $-0.34, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 8.05% year-over-year and EPS growth of -10.06% year-over-year. On the balance sheet, it maintains a current ratio of 37.28x, a quick ratio of 36.80x, working capital of $316.97M, a debt-to-equity ratio of 0.03x, a debt ratio of 0.03, an interest coverage ratio of -51350.00x, free cash flow of $-52.87M (TTM), and net debt of $-54.30M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.92B
- P/E TTM
- -57.15x
- EPS TTM
- $-0.33
- P/B TTM
- 9.08x
- ROE TTM
- -19.66%
- ROA TTM
- -18.97%
- Debt To Equity
- 0.03x
- Free Cash Flow TTM
- $-52.87M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Trevi Therapeutics, Inc. in?
Trevi Therapeutics, Inc. (TRVI) operates in the Pharmaceutical Preparations industry.
What exchange does TRVI trade on?
Trevi Therapeutics, Inc. (TRVI) trades on the Nasdaq.
Where is Trevi Therapeutics, Inc. incorporated?
Trevi Therapeutics, Inc. is incorporated in DE.
When was Trevi Therapeutics, Inc. (TRVI)'s most recent SEC filing?
Trevi Therapeutics, Inc. (TRVI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is TRVI's market cap?
Trevi Therapeutics, Inc. (TRVI) has a market capitalization of $2.92B as of 2026-06-30.
What is TRVI's EPS (earnings per share)?
Trevi Therapeutics, Inc. (TRVI)'s trailing twelve month EPS is $-0.33 as of 2026-06-30.
What is TRVI's ROE (return on equity)?
Trevi Therapeutics, Inc. (TRVI)'s trailing twelve month Return on Equity (ROE) is -19.66% as of 2026-06-30.
What is TRVI's ROA (return on assets)?
Trevi Therapeutics, Inc. (TRVI)'s trailing twelve month Return on Assets (ROA) is -18.97% as of 2026-06-30.
What is TRVI's ROIC (return on invested capital)?
Trevi Therapeutics, Inc. (TRVI)'s trailing twelve month Return on Invested Capital (ROIC) is -34.12% as of 2026-06-30.
What is TRVI's EV/EBITDA?
Trevi Therapeutics, Inc. (TRVI)'s trailing twelve month EV/EBITDA is -48.24x as of 2026-06-30.